Eradication of Helicobacter pylori: Are rifaximin-based regimens effective?

Digestion

Volumn 73, Issue SUPPL. 1, 2006, Pages 129-135

  Gasbarrini, Antonio ^a   Gasbarrini, Giovanni ^a   Pelosini, Iva ^b   Scarpignato, Carmelo ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Adverse events; Antibiotic; Dual and triple therapies; Helicobacter pylori; Helicobacter, eradication rate; Rifabutin; Rifamycin; Rifaximin

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE BISMUTH CITRATE; RIFABUTIN; RIFAMPICIN; RIFAXIMIN; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BONE MARROW TOXICITY; CHROMOSOME MUTATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTIOUS DIARRHEA; LEUKOPENIA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; STOMACH PH; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT FAILURE; UREA BREATH TEST;

ANTI-INFECTIVE AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RIFAMYCINS; TREATMENT OUTCOME;

EID: 33644502571     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089788     Document Type: Review

References (74)

1. Marshall BJ, Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;i:1311-1315.
2. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P: A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-1958.
3. Cremonini F, Gasbarrini A, Armuzzi A, Gasbarrini G: Helicobacter pylori-related diseases. Eur J Clin Invest 2001;31:431-437.
4. International Agency for Research on Cancer: Infection with Helicobacter pylori; in IARC Monographs Vol. 61: Schistosomes, Liver Flukes and Helicobacter pylori. Lyon, IARC, 1994, pp 177-202.
5. Misiewicz JJ: Is the only good Helicobacter a dead Helicobacter? Helicobacter 1997;2(suppl 1):S89-S91.
6. Graham DY: The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 1997;350:70-71.
7. Vaira D, Vakil N, Rugge M, Gatta L, Ricci C, Menegatti M, Leandro G, Holton J, Russo VM, Miglioli M: Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut 2003;52:1543-1547.
8. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
9. Zarrilli R, Ricci V, Romano M: Molecular response of gastric epithelial cells to Helicobacter pylori-induced cell damage. Cell Microbiol 1999;1:93-99.
10. Ricci V, Zarrilli R, Romano M: Voyage of Helicobacter pylori in human stomach: odyssey of a bacterium. Dig Liver Dis 2002;34:2-8.
11. Uemura N, Okamoto S, Yamamoto S, et al: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
12. Peek RM Jr, Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
13. Helicobacter Cancer Collaborative Group: Gastric cancer and Helicobacter pylori: a combined analysis of 12 case-control studies nested within prospective cohorts. Gut 2001;49:347-353.
14. Scarpignato C, Pelosini I: Antisecretory drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. Prog Basic Clin Pharmacol 1999;11:136-180.
15. Scarpignato C: Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis 2004;36:243-247.
16. Makristathis A, Hirschl AM, Lehours P, Mégraud F: Diagnosis of Helicobacter pylori infection. Helicobacter 2004;9(suppl 1):7-14.
17. 13C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004;20:1001-1017.
18. 13C-urea breath test for non-invasive diagnosis of Helicobacter pylori infection: which procedure and which measuring equipment? Eur J Gastroenterol Hepatol 2001;13:803-806.
19. Gisbert JP, Pajares JM: Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review. Am J Gastroenterol 2001;96:2829-2838.
20. Parente F, Maconi G, Porro GB, Caselli M: Stool test with polyclonal antibodies for monitoring Helicobacter pylori eradication in adults: a critical reappraisal. Scand J Gastroenterol 2002;37:747-749.
21. Romano M, Cuomo A: Eradication of Helicobacter pylori: a clinical update. MedGenMed 2004;6:19 [available at http://www.pubmed-central.gov/articlerender. fcgi?artid = 1140724].
22. McLoughlin RM, O'Morain CA, O'Connor HJ: Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol 2005;19:421-427.
23. Candelli M, Nista EC, Carloni E, Pignataro G, Zocco MA, Cazzato A, Di Campli C, Fini L, Gasbarrini G, Gasbarrini A: Treatment of H. pylori infection: a review. Curr Med Chem 2005;12:375-384.
24. Ford AC, Delaney BC, Forman D, Moayyedi P: Eradication therapy in Helicobacter pylori-positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-1855.
25. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A: Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002;16:1269-1275.
26. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F, Rinaldi V, Perri F, Papadia C, Fornari F, Pilati S, Mete LS, Merla A, Poti R, Marinone G, Savioli A, Campo SM, Faleo D, Ierardi E, Miglioli M, Morini S: High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-726.
27. De Boer WA, Kuipers EJ, Kusters JG: Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use? Dig Liver Dis 2004;36:311-314.
28. Gisbert JP, Pajares JM: Review article: Helicobacter pylori 'rescue' regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057.
29. Mégraud F, Lamouliatte H: Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-1343.
30. Parente F, Cucino C, Bianchi Porro G: Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003;35:523-528.
31. Di Mario F, Cavallaro LG, Scarpignato C: Rescue therapies for management of Helicobacter pylori infection. Dig Dis 2006; in press.
32. Graham DY, de Boer WA, Tytgat GNJ: Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072-1076.
33. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN: A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-1055.
34. Mégraud F: Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug Resist Updat 2001;4:178-186.
35. Pilotto A, Franceschi M, Rassu M, Furlan F, Scagnelli M: In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol 2000;95:833-834.
36. Heep M, Beck D, Bayerdorffer E, Lehn N: Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-1499.
37. Jiang ZD, DuPont HL: Rifaximin: in vitro and in vivo antibacterial activity. A review. Chemotherapy 2005;51(suppl 1):67-72.
38. Brogden RN, Fitton A: Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:983-1009.
39. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM: 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003;8:90-94.
40. Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH, Yee YK, Chan CK, Xia HH, Yuen MF, Wong BC: Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:553-560.
41. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A: Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-316.
42. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr: Adverse events associated with high-dose ritabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-598.
43. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A: Rifabutin-based Helicobacter pylori eradication rescue therapy. Aliment Pharmacol Ther 2001;15:143.
44. Finch CK, Chrisman CR, Baciewicz AM, Self TH: Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985-992.
45. Zullo A, Hassan C, Campo SMA, Morini S: Evolving therapy for Helicobacter pylori infection. Exp Opin Ther Patents 2004, 14:1453-1464.
46. Scarpignato C, Pelosini I: Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 21):36-66.
47. Ericsson CD, DuPont HL: Rifaximin in the treatment of infectious diarrhea. Chemotherapy 2005;51(suppl 1):73-80.
48. Gerard L, Garey KW, DuPont HL: Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3:201-211.
49. Baker DE: Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005;5:19-30.
50. Huang DB, DuPont HL: Rifaximin - a novel antimicrobial for enteric infections. J Infect 2005;50:97-106.
51. Mignini F, Falcioni E, Prenna M, Santacroce F, Ripa S: In vitro antibacterial activity of rifaximin against Campylobacter pylori (Campylobacter pyloridis). Chemiotherapia (Florence) 1989;1(suppl 4):222-223.
52. Mégraud F, Bouffant F, Camou Juncas C: In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1994;13:184-186.
53. Holton J, Vaira D, Menegatti M, Barbara L: The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother 1995;35:545-549.
54. Quesada M, Sanfeliu I, Junquera F, Segura F, Calvet X: Evaluation of Helicobacter pylori susceptibility to rifaximin (in Spanish). Gastroenterol Hepatol 2004;27:393-396.
55. Pretolani S, Bonvicini F, Brocci E, Cilla D, Pasini P, Baldini L, Epifanio G, Miglio F, Gasbarrini G: Effect of rifaximin, a new non-absorbed antibiotic, in the treatment of Helicobacter pylori infection. Acta Gastroenterol Belg 1993;56:144A.
56. De Giorgio R, Stanghellini V, Barbara G, Guerrini S, Ferrieri A, Corinaldesi R: Rifaximin and Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 1997;1:105-110.
57. Dell'Anna A, Azzarone P, Ferrieri A: A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori. Eur Rev Med Pharmacol Sci 1999;3:105-110.
58. Atherton JC, Washington N, Bracewell MA, Sutton LJ, Greaves JL, Perkins AC, Hawkey CJ, Spiller RC: Scintigraphic assessment of the intragastric distribution and gastric emptying of an encapsulated drug: the effect of feeding and of a proton pump inhibitor. Aliment Pharmacol Ther 1994;8:489-494.
59. Gottfries J, Svenheden A, Alpstein M, Bake B, Larsson A, Idstrom JP: Gastrointestinal transit of amoxicillin modified-release tablets and a placebo tablet including pharmacokinetic assessments of amoxicillin. Scand J Gastroenterol 1996;31:49-53.
60. Grant R, Grossman MI, Ivy AC: Histological changes in the gastric mucosa during digestion and their relationship to mucosal growth. Gastroenterology 1953;25:218-231.
61. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A: Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-35.
62. Gasbarrini A, Lauritano EC, Nista EC, Candelli M, Gabrielli M, Santoro M, Zocco MA, Cazzato A, Finizio R, Ojetti V, Cammarota G, Gasbarrini G: Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis 2006; in press.
63. Vaira D, Menegatti M, Miglioli M, Ferrieri A et al: Rifaximin suspension for the eradication of Helicobacter pylori. Curr Ther Res 1997;58:300-308.
64. McLoughlin R, O'Morain C: Effectiveness of anti-infectives. Chemotherapy 2005;51:243-246.
65. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A: Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-316.
66. Wong WM, Gu Q, Lam SK, Fung FM, Lai KC, Hu WH, Yee YK, Chan CK, Xia HH, Yuen MF, Wong BC: Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:553-560.
67. Toracchio S, Capodicasa S, Soraja DB, Cellini L, Marzio L: Rifabutin-based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005;37:33-38
68. Munoz DJB, Tasman Jones C, Pybus J: Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus. Gut 1992;33:592-596.
69. McNulty AM, Dent JC, Ford GA, Wilkinson SP: Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988;22:729-738.
70. Conway BR: Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr Pharm Des 2005;11:775-790.
71. Wanlian Pharmaceutical Co Ltd: Rifaximin soft capsule composition [CN1451386] 2002.
72. Huynh HQ, Couper RT, Tran CD, Moore L, Kelso R, Butler RN: N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Dig Dis Sci 2004;49:1853-1861.
73. Gotoh A, Akamatsu T, Shimizu T, Shimodaira K, Kaneko T, Kiyosawa K, Ishida K, Ikeno T, Sugiyama A, Kawakami Y, Ota H, Katsuyama T: Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter 2002;7:183-191.
74. Hilal RE, Hilal T: The efficacy and tolerability of riofaximin, doxycycline and lansoprazole in the treatment of H. pylori gastritis: an open label pilot study. Am J Gastroenterol 2005;100(suppl):S57.